Your search for major depressive disorder returned 68 results

Active Filters

Click on a filter below to refine your search. Remove a filter to broaden your search.

Last 12 months remove

Your search for major depressive disorder returned 68 results

Sort Results:

Relevant Recent
Neurobehavioral Disorders

Ketamine Infusions Improve Symptoms of Depression and Pain

Patients with treatment-resistant major depressive disorder or bipolar disorder without psychotic symptoms received intravenous infusions of 0.5 mg/kg ketamine 3 times per week for 2 weeks.
Neurobehavioral Disorders

USPSTF Recommends Anxiety, Depression Screening for Children

The US Preventive Services Task Force (USPSTF) recommends screening for major depressive disorder (MDD) in adolescents aged 12 to 18 years, and recommends anxiety screening for children aged 8 to 18 years.
Neurobehavioral Disorders

Sleep Disturbances Impact Web-Based CBT Outcomes

The researchers of this study explored the impact of a blended approach (bCBT) that included both face-to-face CBT and iCBT on patients with major depressive disorder and insomnia.

Management of “Off” Episodes in Parkinson Disease: Novel Advancements From 2022 American Academy of Neurology Annual Meeting

The American Academy of Neurology hosted its 74th annual meeting in Seattle, Washington. Michael S. Okun, MD, shares his key takeaways from the plethora of sessions discussing advancements in the management of “off” episodes for patients with Parkinson disease. New drug delivery systems and formulations for carbidopa/levodopa (CD/LD) are among the exciting changes from the 2022 AAN meeting.

Spinal Muscular Atrophy as a Treatable Disease: Disease-Modifying Therapies Improving Clinical Outcomes and Quality of Life

Spinal muscular atrophy is one of the most common causes of infant mortality. Historically, SMA treatment consisted of supportive care only. The arrival of disease-modifying therapies has made a major impact on the prognosis for patients with SMA. This article highlights therapies approved by the FDA, such as survival motor neuron 2 (SMN2) modulators, SMN1 gene therapy, and the use of newborn screening to commence treatment in the pre-symptomatic period.
Next post in General Neurology